Develop Late-Stage Clinical Cart-DDBCMA In Multiple Myeloma

Arcellx

09/12/2022 13:55

Dec 9 (Reuters) - Arcellx Inc  ACLX.O :
    * ARCELLX AND KITE ANNOUNCE STRATEGIC COLLABORATION TO
CO-DEVELOP
AND CO-COMMERCIALIZE LATE-STAGE CLINICAL CART-DDBCMA IN MULTIPLE
MYELOMA
    * ARCELLX INC- ARCELLX TO RECEIVE $225M UPFRONT PAYMENT;
$100M
EQUITY INVESTMENT; AND UP TO $3.9B IN TOTAL CONTINGENT
CONSIDERATION
    * ARCELLX INC - COMPANIES TO CO-COMMERCIALIZE AND SPLIT
PROFITS IN
U.S.; ARCELLX TO RECEIVE LOW TO MID-TEEN ROYALTIES OUTSIDE U.S.
    * ARCELLX INC- ARCELLX TO CONTINUE INDEPENDENTLY PROGRESSING
ITS
DEVELOPMENT PIPELINE AND RESEARCHING NEW PRODUCT CANDIDATES
BEYOND MYELOMA
    * ARCELLX INC - OUTSIDE US, KITE WILL COMMERCIALIZE PRODUCT
AND
ARCELLX WILL RECEIVE ROYALTIES ON SALES
    * ARCELLX INC - AFTER COMPLETION OF TECHNICAL TRANSFER, KITE
WILL
BE RESPONSIBLE FOR MANUFACTURING OF CART-DDBCMA

Source text for Eikon:  ID:nPn6L6KbVa 
Further company coverage:  ACLX.O 
 ((Reuters.Briefs@thomsonreuters.com;))